Zealand Pharma A/S – Product Pipeline Review

Global Markets Direct’s, ‘Zealand Pharma A/S – Product Pipeline Review – 2016’, provides an overview of the Zealand Pharma A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Zealand Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Zealand Pharma A/S

The report provides overview of Zealand Pharma A/S including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Zealand Pharma A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Zealand Pharma A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Zealand Pharma A/S’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Zealand Pharma A/S

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Zealand Pharma A/S’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Zealand Pharma A/S Snapshot 5

Zealand Pharma A/S Overview 5

Key Information 5

Key Facts 5

Zealand Pharma A/S - Research and Development Overview 6

Key Therapeutic Areas 6

Zealand Pharma A/S - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Zealand Pharma A/S - Pipeline Products Glance 14

Zealand Pharma A/S - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Zealand Pharma A/S - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Zealand Pharma A/S - Drug Profiles 17

ZP-1848 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

ZP-4207 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

ZP-2929 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Synthetic Peptide for Diabetes and Obesity 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Synthetic Peptides for Undisclosed Indications 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ZP-3022 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ZPDI-70 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ZPGG-23 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ZPGG-72 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ZPI-98 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Zealand Pharma A/S - Pipeline Analysis 27

Zealand Pharma A/S - Pipeline Products by Target 27

Zealand Pharma A/S - Pipeline Products by Route of Administration 28

Zealand Pharma A/S - Pipeline Products by Molecule Type 29

Zealand Pharma A/S - Pipeline Products by Mechanism of Action 30

Zealand Pharma A/S - Recent Pipeline Updates 31

Zealand Pharma A/S - Dormant Projects 34

Zealand Pharma A/S - Locations And Subsidiaries 35

Head Office 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Zealand Pharma A/S, Key Information 5

Zealand Pharma A/S, Key Facts 5

Zealand Pharma A/S – Pipeline by Indication, 2016 7

Zealand Pharma A/S – Pipeline by Stage of Development, 2016 8

Zealand Pharma A/S – Monotherapy Products in Pipeline, 2016 9

Zealand Pharma A/S – Partnered Products in Pipeline, 2016 10

Zealand Pharma A/S – Partnered Products/ Combination Treatment Modalities, 2016 11

Zealand Pharma A/S – Out-Licensed Products in Pipeline, 2016 12

Zealand Pharma A/S – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Zealand Pharma A/S – Phase II, 2016 14

Zealand Pharma A/S – Phase I, 2016 15

Zealand Pharma A/S – Preclinical, 2016 16

Zealand Pharma A/S – Pipeline by Target, 2016 27

Zealand Pharma A/S – Pipeline by Route of Administration, 2016 28

Zealand Pharma A/S – Pipeline by Molecule Type, 2016 29

Zealand Pharma A/S – Pipeline Products by Mechanism of Action, 2016 30

Zealand Pharma A/S – Recent Pipeline Updates, 2016 31

Zealand Pharma A/S – Dormant Developmental Projects,2016 34

List of Figures

List of Figures

Zealand Pharma A/S – Pipeline by Indication, 2016 7

Zealand Pharma A/S – Pipeline by Stage of Development, 2016 8

Zealand Pharma A/S – Monotherapy Products in Pipeline, 2016 9

Zealand Pharma A/S – Partnered Products in Pipeline, 2016 10

Zealand Pharma A/S – Out-Licensed Products in Pipeline, 2016 12

Zealand Pharma A/S – Pipeline by Target, 2016 27

Zealand Pharma A/S – Pipeline by Route of Administration, 2016 28

Zealand Pharma A/S – Pipeline by Molecule Type, 2016 29

Zealand Pharma A/S – Pipeline Products by Mechanism of Action, 2016 30

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports